AMRN:NSD-Amarin Corporation plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.72

Change

-0.11 (-1.89)%

Market Cap

USD 2.29B

Volume

8.63M

Average Target Price

USD 10.17 (+77.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Company Website : http://www.amarincorp.com

Address : Grand Canal Docklands, Dublin, Ireland, 2

Employees : 1,000

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.38

52 Week High : 14.70

Short Ratio : 2.45

52 Week Low : 3.36

Shorted Shares : 20,135,782

200 Day Moving Average : 5.57

Shorted Shares Previous Month : 20,211,653

50 Day Moving Average : 7.27

Shares Held By Insiders : 10.34%

Short Percentage : 5.00%

Shares Held by Institutions : 39.44%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.65 (-0.31%)

 USD54.19B 20.26 15.08
MRNA Moderna, Inc

+1.08 (+0.82%)

 USD52.46B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

+2.65 (+0.59%)

 USD47.86B 14.64 11.87
ALXN Alexion Pharmaceuticals, Inc

+0.27 (+0.18%)

 USD32.58B 54.48 33.22
BGNE BeiGene, Ltd

-15.33 (-5.03%)

 USD29.17B N/A N/A
SGEN Seagen Inc

-2.48 (-1.68%)

 USD26.80B 43.90 37.70
RPRX Royalty Pharma plc

-1.23 (-2.82%)

 USD26.45B 22.60 14.17
BNTX BioNTech SE

-2.10 (-2.16%)

 USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.63 (-5.01%)

 USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing AMRN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.97% 68% D+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.97% 68% D+ 70% C-
Trailing 12 Months  
Capital Gain -62.98% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.98% 3% F 2% F
Trailing 5 Years  
Capital Gain 273.86% 84% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 273.86% 84% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 107.92% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 107.92% 91% A- 96% A
Risk Return Profile  
Volatility (Standard Deviation) 210.23% 10% F 5% F
Risk Adjusted Return 51.34% 78% C+ 72% C-
Market Capitalization 2.29B 83% B 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.41 61% D- 41% F
Price / Cash Flow Ratio -105.53 95% A 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -2.91% 91% A- 49% F
Return on Invested Capital -3.17% 86% B 41% F
Return on Assets -1.33% 92% A- 41% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.45 50% F 47% F
Short Percent N/A N/A N/A N/A N/A
Beta 2.38 12% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.